Sandeep Chhabra, MD
Interventional Cardiology · Bowling Green, KYNPI 1205887858
Payments from drug & device makers
Across 376 payments — averaging $48.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$7K
- Boston Scientific$2K
- Medtronic$2K
- Biosense Webster, Inc.$1K
- Baylis Medical Company Inc$1K
- Novartis$881
- plus $4K from 34 others
What the payments were for
- Travel & lodging$9,02850%
- Food & beverage$7,86643%
- Education$1,1056%
- Entertainment$840%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 56 | $6,578 |
| Boston Scientific | 42 | $2,015 |
| Medtronic(2 entities) | 12 | $1,631 |
| Biosense Webster, Inc. | 11 | $1,356 |
| Baylis Medical Company Inc | 3 | $1,248 |
| Novartis | 66 | $881 |
| Abiomed | 16 | $795 |
| Johnson & Johnson | 63 | $785 |
| Penumbra, Inc. | 3 | $591 |
| Pfizer | 18 | $276 |
| Shockwave Medical, Inc | 5 | $268 |
| Inari Medical, Inc. | 3 | $178 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $165 |
| Chiesi USA, Inc. | 8 | $145 |
| Amgen | 9 | $143 |
| Bayer | 1 | $128 |
| Boehringer Ingelheim | 5 | $86 |
| Sanofi-aventis U.S. LLC | 5 | $86 |
| Terumo Medical Corporation | 4 | $79 |
| Actelion Pharmaceuticals US, Inc. | 3 | $73 |
| Merck | 4 | $60 |
| Halozyme Inc | 1 | $50 |
| E.r. Squibb & Sons, L.L.C. | 3 | $45 |
| Braemar Manufacturing, LLC | 1 | $44 |
| Novo Nordisk | 2 | $43 |
| AstraZeneca | 3 | $43 |
| Esperion Therapeutics, Inc. | 2 | $39 |
| Amarin Pharma, Inc. | 2 | $33 |
| Preventice Services, LLC | 2 | $27 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Biotronik Inc. | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Lundbeck LLC | 1 | $17 |
| Lexicon Pharmaceuticals, Inc. | 1 | $17 |
| Livanova USA, Inc. | 1 | $16 |
| Thrombolex, Inc. | 1 | $16 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $15 |
| Inspire Medical Systems, Inc. | 1 | $14 |
| EKOS Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AVEIR$1,753
- AMPLATZER AMULET$1,455
- Watchman$1,174
- Carto 3$1,139
- EVERA MRI XT DR SURESCAN$1,128
- NRG needle$1,082
- ASSURITY$740
- MitraClip$634
- Indigo System$555
- DRAGONFLY OPSTAR$552
- OPTIS$422
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$188
- Impella$145
- AURORA EV-ICD MRI SURESCAN$143
- Kerendia$128
How this compares
$18,084 in reported general payments places this provider in the 60th percentile of 129 interventional cardiology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 108 | $96,825 |
| JardianceEmpagliflozin | 60 | $53,604 |
| EntrestoSacubitril/Valsartan | 42 | $25,826 |
| FarxigaDapagliflozin Propanediol | 27 | $22,459 |
| BrilintaTicagrelor | 27 | $15,819 |
| Ranolazine ErRanolazine | 55 | $3,066 |
| Metoprolol Succinate | 121 | $1,523 |
| Rosuvastatin Calcium | 71 | $612 |
| Nebivolol Hcl | 12 | $423 |
| ClopidogrelClopidogrel Bisulfate | 82 | $401 |
| Ezetimibe | 27 | $350 |
| Ramipril | 14 | $341 |
| Atorvastatin Calcium | 37 | $258 |
| Losartan Potassium | 26 | $236 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 25 | $163 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $276 | $96,825108 claims |
| Boehringer IngelheimJardiance | $86 | $53,60460 claims |
| AstraZenecaFarxiga, Brilinta | $43 | $38,27854 claims |
| NovartisEntresto | $881 | $25,82642 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 129 interventional cardiology providers in Kentucky.
Other interventional cardiology in Bowling Green
- Jerry RoyBowling Green$180K
- Rahil RafeedheenBowling Green$31K
- Mohammed KazimuddinBowling Green$17K
- Thomas TuLouisville$1.4M
- Amit SrivastavaEdgewood$736K
- Avichai EresLexington$616K
- Naresh SolankhiLouisville$545K
- Sreedevi GondiLouisville$535K
- Steve LinLexington$372K
- Daniel StewartLouisville$290K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.